Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
The inspection closed with the facility receiving an inspection classification of NAI
Convergent action on AMR identified as an important area of intervention
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg had annual sales of USD 42 mn in the United States (IQVIA MAT April 2023)
Subscribe To Our Newsletter & Stay Updated
